Copyright
©The Author(s) 2021.
World J Transplant. Dec 18, 2021; 11(12): 512-522
Published online Dec 18, 2021. doi: 10.5500/wjt.v11.i12.512
Published online Dec 18, 2021. doi: 10.5500/wjt.v11.i12.512
Table 1 Clinical characteristics and tuberculin skin test results of 213 cirrhotic patients who underwent liver transplantation between January 2005 and December 2012, n (%)
| Characteristic | General | TST positive | TST negative | P1 |
| (n = 213) | (n = 35) | (n = 178) | ||
| Age (yr) | 53.2 ± 11.0 | 56.1 ± 8.6 | 52.6 ± 11.3 | 0.13 |
| Male | 153 (71.8) | 25 (71.4) | 128 (71.9) | 0.95 |
| Cirrhosis etiology | ||||
| Viral hepatitis | 68 (31.9) | 12 (34.3) | 56 (31.5) | |
| Alcoholic | 64 (30.0) | 13 (37.1) | 51 (28.7) | |
| Cryptogenic | 45 (21.1) | 6 (17.1) | 39 (21.9) | 0.01 |
| AIH, PBC, PSC | 27 (12.7) | 0 (0) | 27 (15.2) | |
| Other etiologies | 9 (4.2) | 4 (11.4) | 5 (2.8) | |
| Previous contact with TB patients | 18 (8.5) | 6 (20.0) | 12 (8.3) | 0.09 |
| Hepatocellular carcinoma | 41 (19.2) | 11 (31.4) | 30 (16.9) | 0.046 |
| MELD score | 16.4 ± 5.0 | 15.4 ± 4.0 | 16.6 ± 5.1 | 0.22 |
| MELD Na | 18.2 ± 5.3 | 16.5 ± 4.5 | 18.5 ± 5.4 | 0.045 |
| Child | ||||
| Child A | 39 (18.3) | 11 (31.4) | 28 (15.7) | |
| Child B | 107 (50.2) | 14 (40.0) | 93 (52.2) | 0.136 |
| Child C | 67 (31.5) | 10 (28.6) | 57 (32.0) | |
| Hemoglobin | 12.2 ± 1.9 | 12.6 ± 2.3 | 12.1 ± 1.7 | 0.257 |
| Creatinine (mg/dL) | 0.99 ± 0.62 | 0.93 ± 0.25 | 1.00 ± 0.67 | 0.471 |
| Albumin (g/dL) | 3.1 ± 0.6 | 3.3 ± 0.8 | 3.1 ± 0.5 | 0.181 |
| Sodium (mEq/L) | 137.7 ± 4.7 | 139.5 ± 4.6 | 137.3 ± 4.7 | 0.043 |
| Bilirubin (mg/dL) | 4.33 ± 5.96 | 2.92 ± 1.76 | 4.60 ± 6.44 | 0.364 |
| INR | 1.62 ± 0.43 | 1.59 ± 0.39 | 1.62 ± 0.44 | 0.795 |
Table 2 Usage time of isoniazid and reason for drug withdraw in patients with positive tuberculin skin test
| Patient | Usage time (d) | Reason for drug withdraw |
| Patient 1 | > 180 | LTBI treatment complete |
| Patient 2 | > 180 | LTBI treatment complete |
| Patient 3 | > 180 | LTBI treatment complete |
| Patient 4 | 57 | Changes in liver enzymes |
| Patient 5 | 80 | Cholestasis |
| Patient 6 | 93 | Clinical worsening - polyserositis |
| Patient 7 | 112 | Not justified |
| Patient 8 | 142 | Not justified |
| Patient 9 | 146 | Not justified |
| Patient 10 | 162 | Not justified |
| Patient 11 | 171 | Not justified |
| Patient 12 | 172 | Not justified |
- Citation: Lauar ID, Faria LC, Romanelli RMC, Clemente WT. Latent tuberculosis: Risk factors, screening and treatment in liver transplantation recipients from an endemic area. World J Transplant 2021; 11(12): 512-522
- URL: https://www.wjgnet.com/2220-3230/full/v11/i12/512.htm
- DOI: https://dx.doi.org/10.5500/wjt.v11.i12.512
